BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (March 2018)

26 slides from BioSpecifics Technologies's investor presentation, Mar 26, 2018

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    \o —— —S é \ ae , Innovators in the development & commercialization of ra INJECTABLE COLLAGENASE e —_ = Cp. BioSpecifics March 2018

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: Company Overview

    Company Overview (NASDAQ: BSTC OOOSCEe Originator of collagenase based-therapies Positive clinical results for XIAFLEX (collagenase clostridium histolyticum or CCH) reported in 12 indications to date Profitable biopharma company with lean corporate structure Receives revenues from XIAFLEX® milestone

  4. Slide 4: XIAFLEX Pipeline

    XIAFLEX® Pipeline Approved indications Dupuytren’s Contracture @endo Peyronie's Disease endo | Cellulite endo Top-line data expected in 1019 Adhesive Capsultis ndo Endo is currentty opted-in Human Lipoma endo Endo is currently opted-in Canine Lipoma endo Endo is currentiy opted-in Endo is currently

  5. Slide 5: Marketed XIAFLEX Indications: Dupuytren's Contracture & Peyronie's Disease

    fridivm histoyticum ss Marketed XIAFLEX® Indications: Dupuytren’s Contracture & Peyronie’s Disease

  6. Slide 6: XIAFLEX 4Q and Full Year 2017 Total Revenues

    XIAFLEX 4Q and Full Year 2017 Total Revenues Fourth quarter 2017 total revenues were $61.3M vs. $55.5M for the fourth quarter of 2016, a 10% increase Full year 2017 total revenues were $213.4M vs. $189.7M for the full year of 2016, a 12% increase

  7. Slide 7: XIAFLEX Future Growth Opportunities

    XIAFLEX Future Growth Opportunities Endo expects low to mid-teens percentage growth for XIAFLEX revenue in 2018 Sizable opportunity for growth Of the patients diagnosed with Peyronie’s disease, 85-90% are untreated and for Dupuytren’s contracture 75-80% are untreated FUTURE GROWTH INITIATIVES: Dupuy

  8. Slide 8: XIAFLEX for Dupuytren's Contracture

    for Dupuytren’s Contracture Definition & Key Complications Deforming condition of the hand in which one or more fingers contracts toward the palm Limits range of motion and impairs quality of life Affects between 3-9% of adult Caucasians Pre-treatment: Post-treatment: aA ‘Source: Endo International

  9. Slide 9: XIAFLEX for Peyronie's Disease

    XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self

  10. Slide 10: CCH Pipeline Indications

    CCH Pipeline Indications

  11. Slide 11: Overview of CCH for Uterine Fibroids

    Overview of CCH for Uterine Fibroids Definition & Key Complications US. Market Opportunity Phase 1 Trial Design Benign tumors in the reproductive tract that contain large amounts of collagen Cause pelvic discomfort and pain, decreased fertility, pregnancy complications, increased rate of miscarriage

  12. Slide 12: Positive Interim Results from Ongoing Phase 1 Trial for Uterine Fibroids

    Positive Interim Results from Ongoing Phase 1 Trial for Uterine Fibroids Phase 1 initiated based on preclinical data published in May 2016 issue of American Journal of Obstetrics & Gynecology showed highly purified collagenase can reduce stiffness of human uterine fibroid tissue ex-vivo Interim data

  13. Slide 13: Potential Advantages of XIAFLEX

    Potential Advantages of XIAFLEX Injection vs. Major Surgery Shorter, Easier Process 5-10 minutes vs. 2-4 hours for hysterectomy and myomectomy and 1-2 hours for uterine artery embolization No intubation Sedation vs. anesthesia for surgery Limited Recovery Time “Lost work” costs of $4,500-$30,000 per

  14. Slide 14: Overview of CCH Potential for Cellulite

    Overview of CCH Potential for Cellulite OVERVIEW Contour abnormality of the skin resulting in dimpling Skin dimpling caused by tethering of fibrous septae with fat cell volume as secondary cause, occurring mainly on the buttocks, thighs and lower abdomen and arms Affects “85-90% of post-pubertal fem

  15. Slide 15: Phase 3 Clinical Trials for Cellulite

    Phase 3 Clinical Trials for Cellulite Initiated in February 2018 Top-line results expected in the first quarter of 2019 Two ongoing identical Phase 3 RELEASE clinical trials of CCH for the treatment of cellulite Multicenter, randomized, double-blind, placebo-controlled studies to evaluate the safety

  16. Slide 16: CCH for Adhesive Capsulitis

    CCH for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy * Inflammation and thickening of shoulder capsule due to collagen * Limits range of motion of shoulder = Common available treatment options are often painful and can require anesthesia Long-term intensive physical ther

  17. Slide 17: CCH for Plantar Fibromatosis

    CCH for Plantar Fibromatosis Definition & Complications ~200,000 patients in the U.S. Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, Peyronie’s disease and adhesive cap

  18. Slide 18: CCH for Human Lipomas

    CCH for Human Lipomas Encapsulated deposits of benign fat, often detected as bulges under the skin No FDA-approved pharmaceutical therapies available Potential to be Only FDA-Approved Offers an alternative to patients that may choose to avoid surgery, and avoid surgically-related complications (hema

  19. Slide 19: Positive Top-Line Phase 2 Study Results

    Positive Top-Line Phase 2 Study Results Single 0.58 mg Injection of CCH Primary endpoint: 81.3% reduction in visible surface area for CCH vs. 2.1% increase for placebo; 83.4% difference in favor of CCH (p<0.0001) 89.5% responder rate (showed a >50% decrease in lipoma visible surface area relative to

  20. Slide 20: CCH for Lateral Hip Fat

    CCH for Lateral Hip Fat Definition & Complications = Similar prevalence to cellulite = Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone = Patients frequently avoid exercise and are unable to restrict their

  21. Slide 21: Additional Promising Unlicensed Indications

    Additional Promising Unlicensed Indications Capsular Contracture, Breast Hypertrophic Scars & Keloids Dercum’s Disease Knee Arthrofibrosis Urethral Strictures ‘Source: Endo International ple Post-surgical complication that can deform the breast and cause pain Scars that form on the skin at site of i

  22. Slide 22: Endo Partnership for Development and Commercialization of XIAFLEX

    Endo Partnership for Development and Commercialization of XIAFLEX® >$133M Received as of December 31, 2017 $133M received in licensing, sublicensing, milestone, COGS, and royalty payments as of December 31, 2017 Low double digit royalties as % of net sales Future Payments Additional mark-up on COGS

  23. Slide 23: Strong IP Portfolio

    Strong IP Portfolio Dupuytren’s Contracture Biologic Exclusivity until 2022 Drug product composition patent until 2028 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Uterine Fibroids Method of use patent until 2034 Patents and Patent Applicati

  24. Slide 24: Consistently Profitable Annually

    Consistently Profitable Annually Financial Highlights (unaudited) For the years ended 12/31/2017 12/31/2016 Cash and equivalents, and investments $65,053,756 $52,789,606 Income Statement Revenues $27,443,752 $26,250,955 Other income 687,642 348,588 Costs and expenses (9,765,601) (9,224,539) Provisio

  25. Slide 25: BioSpecifics Corporate and Clinical Highlights

    BioSpecifics Corporate and Clinical Highlights BioSpecifics continues to be profitable on an ongoing basis Top-line data from BioSpecifics-sponsored Phase 1 clinical trial in uterine fibroids expected in 2018 Top-line data from Endo-sponsored Phase 3 clinical trials in cellulite expected in 1Q 2019

  26. Slide 26: Innovators in the development & commercialization of injectable collagenase

    4 ™ — ‘2 —— \¢4 . Innovators in the development & commercialization of re INJECTABLE COLLAGENASE @ an ™—~ ep. BioSpecifics March 2018

Biospecifics Technologies — Investor Presentation (March 2018) on 6ix